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Recently, we described a heterologous prime-boost strategy using plasmid DNA followed by replication-
defective human recombinant adenovirus type 5 as a powerful strategy to elicit long-lived CD8 T-cell-
mediated protective immunity against experimental systemic infection of mice with a human intracellular
protozoan parasite, Trypanosoma cruzi. In the present study, we further characterized the protective long-lived
CD8 T cells. We compared several functional and phenotypic aspects of specific CD8 T cells present 14 or
98 days after the last immunizing dose and found the following: (i) the numbers of specific cells were similar,
as determined by multimer staining or by determining the number of gamma interferon (IFN-)-secreting cells
by enzyme-linked immunospot (ELISPOT) assay; (ii) these cells were equally cytotoxic in vivo; (iii) following
in vitro stimulation, a slight decline in the frequency of multifunctional cells (CD107a IFN- or CD107a
IFN- tumor necrosis factor alpha positive [TNF-]) was paralleled by a significant increase of CD107a
singly positive cells after 98 days; (iv) the expression of several surface markers was identical, except for the
reexpression of CD127 after 98 days; (v) the use of genetically deficient mice revealed a role for interleukin-12
(IL-12)/IL-23, but not IFN-, in the maintenance of these memory cells; and (vi) subsequent immunizations
with an unrelated virus or a plasmid vaccine or the depletion of CD4 T cells did not significantly erode the
number or function of these CD8 T cells during the 15-week period. From these results, we concluded that
heterologous plasmid DNA prime-adenovirus boost vaccination generated a stable pool of functional protective
long-lived CD8 T cells with an effector memory phenotype.
Genetic vaccination using the strategy known as the heter-
ologous prime-boost regimen is being pursued as an alternative
type of vaccine. This strategy consists of the use of two differ-
ent vectors, both carrying a gene that encodes the same anti-
genic protein, for priming and boosting immunizations. This
strategy can be particularly important in the case of intracel-
lular pathogens and neoplastic cells, where the effectiveness of
the vaccine relies heavily on its capacity to elicit specific im-
mune responses mediated by cytotoxic CD8 T cells (reviewed
in references 22, 31, 38, 39, and 57).
Among possible genetic vector combinations, heterologous
prime-boost vaccination, which uses a naked plasmid DNA for
priming followed by a booster injection of recombinant repli-
cation-deficient human adenovirus type 5 (HuAd5), has suc-
ceeded in providing protective immunity in some relevant pre-
clinical experimental models, such as simian immunodeficiency
virus (SIV), malaria, and Ebola and Marburg virus models (1,
8, 9, 18, 19, 20, 29, 53). Based on these relative successes
obtained with preclinical experimental models, human trials
have been initiated (17, 26, 28, 43).
Recently, we reported that this strategy could successfully
vaccinate highly susceptible A/Sn mice against systemic infec-
tion with the human intracellular protozoan parasite Trypano-
soma cruzi, the causative agent of Chagas’ disease (American
trypanosomiasis). In these experiments, we used a plasmid
DNA and a human replication-defective adenovirus type 5,
both expressing the amastigote surface protein 2 (ASP-2) of T.
cruzi. Protective immunity generated by vaccination was medi-
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ated by CD4 Th1 and cytotoxic CD8 TC1 cells. Both T-cell
types cooperated to provide the long-lived protective immunity
induced by vaccination, as depletion of either CD4 or CD8
T cells abolished most of the protective immunity. In addition,
perforin and gamma interferon (IFN-) were described as
critical for the acquired immunity of vaccinated animals
against experimental infection with T. cruzi (13).
Vaccinated perforin-deficient or wild-type mice were sus-
ceptible or resistant to T. cruzi infection, respectively. By com-
paring the CD8 T-cell immune responses of these two mouse
strains following heterologous prime-boost vaccination, we ob-
served that both mice had similar numbers of splenic specific
CD8 T cells (13). Nevertheless, the CD8 T cells of the
susceptible perforin-deficient mice had functional defects de-
tected by immunological assays performed in vivo and in vitro
(13).
Considerable information has been published in recent years
about the subsets of memory CD8 T cells elicited following
infections with viruses or bacteria. The current paradigm di-
vides the memory T cells into two major subsets: T effector
memory (TEM) and T central memory (TCM) cells. These
subpopulations can be identified based on their expression of
certain surface markers, such as CD62L and CCR7, and they
may differ greatly in terms of functional and migratory prop-
erties (reviewed in references 4, 25, 36, and 41). In spite of the
fact that rapid knowledge is accumulating on the importance of
each of these populations for long-term CD8 T-cell-mediated
immunity against reinfection with viruses and bacteria, limited
information is available on the roles of these different memory
subsets following vaccination protocols.
Because the functional and phenotypic aspects of long-lived
protective CD8 T cells elicited by heterologous DNA prime-
adenovirus boost vaccination are poorly studied, we considered
that our model could be of interest to clarify this topic. We
accomplished this aim by comparing the functional and phe-
notypic aspects of the transgene-specific protective CD8 T
cells 14 or 98 days following the last immunizing dose with
recombinant HuAd5. We also gained further insights into the
requirement of certain signaling pathways for the maintenance
of these T cells by using genetically deficient mice that do not
express IFN- or interleukin-12 (IL-12)/IL-23 (p40). Finally, to
test whether these cells established a pool of stable functional
CD8 T cells, we subjected these mice to treatments that could
potentially erode either the number or function of specific
CD8 T cells. Overall, we found that these transgene-specific
long-lived CD8 T cells displayed a TEM-like phenotype.
They were dependent on the IL-12/IL-23 (p40) signaling path-
way and relatively resistant to immunological erosion with vac-
cination protocols using either a recombinant virus (modified
vaccinia Ankara virus [MVA]) or plasmid DNA. These results
indicate that long-lived CD8 TEM-like cells elicited by the
heterologous plasmid DNA prime-adenovirus boost vaccina-
tion regimen are a stable pool of functional protective T cells
that can be pursued for the development of vaccines against T.
cruzi, and perhaps other protozoan parasites.
MATERIALS AND METHODS
Mice and parasites. Female 8-week-old C57BL/6 wild-type (WT) or A/Sn mice
were purchased from CEDEME (Federal University of Sa˜o Paulo). IFN- (12)
or IL-12/IL-23 (p40) (33) knockout (KO) mice were raised at the Instituto de
Cieˆncias Biome´dicas, Universidade de Sa˜o Paulo. Parasites of the Y strain of T.
cruzi were used in this study (5). Bloodstream trypomastigotes were obtained
from mice infected 7 days earlier. The concentration of parasites was estimated
and adjusted to 1,500 parasites/ml. Each A/Sn mouse was inoculated subcutane-
ously (s.c.) with 0.1 ml. The use of animals and the experimental procedures,
including the number of mice per experimental group, have been approved by
the Ethics Committee for Animal Care of the Federal University of Sa˜o Paulo
(CEP 0426/09).
Peptide synthesis. The VNHRFTLV peptide and the H-2Kb/VNHRFTLV
pentamer were purchased from Genscript (Piscataway, NJ) and ProImmune Inc.
(Oxford, United Kingdom), respectively.
Recombinant plasmids and adenoviruses used for immunizations. Plasmid
pIgSPclone9 was obtained by inserting the sequence encoding the signal peptide
of the mouse immunoglobulin kappa chain in frame with the gene encoding T.
cruzi amastigote surface protein 2 into the commercial vector pcDNA3 (Invi-
trogen) (5). pAdCMV-ASP2 is an adenoviral transfer plasmid that contains a
eukaryotic expression cassette formed by the cytomegalovirus immediate-early
promoter and simian virus 40 (SV40) RNA polyadenylation sequences. We
cloned the DNA sequences encoding T. cruzi amastigote surface protein 2 ob-
tained by restriction digestion of the plasmid pIgSPclone9 (AdASP-2) (32) within
this cassette. Viruses and plasmids were generated and purified as described
earlier; both led to the expression of the antigen, as evaluated by in vitro trans-
fections (5, 32). Mice were inoculated intramuscularly (i.m.) in each tibialis
anterioris muscle with 50 g of plasmid DNA. Twenty-one days later, these mice
received 50 l of a viral suspension containing 2  108 PFU of adenovirus in the
same locations. Immunological assays were performed 14 or 98 days after viral
inoculation.
Groups of mice vaccinated with the heterologous prime-boost vaccination
regimen were subsequently immunized with a recombinant modified vaccinia
Ankara virus expressing green fluorescent protein (MVA-GFP) (11). This virus
was kindly provided by Flavio da Fonseca of the Federal University of Minas
Gerais, Brazil. Mice were injected intravenously (i.v.) with 107 PFU on the
indicated days (see Fig. 5 and 6). Alternatively, vaccinated mice were immunized
with recombinant plasmid DNA containing the gag gene of HIV (34). This
plasmid was kindly provided by E. T. Marques, Jr., of the Johns Hopkins School
of Medicine, Baltimore, MD.
In vivo depletion of CD4 T cells was achieved by treating vaccinated mice
with the GK1.5 monoclonal antibody (MAb) on the indicated days. Mice were
injected intraperitoneally (i.p.) with three daily doses of 0.5 mg of anti-CD4 or
saline. As determined by fluorescence-activated cell sorter (FACS) analyses, the
depletion of CD4 spleen cells was routinely90% efficient in anti-CD4-treated
mice compared to controls.
Immunological assays. For in vivo cytotoxicity assays, splenocytes collected
from naïve C57BL/6 mice were treated with ACK buffer (NH4Cl, 0.15 M;
KHCO3, 10 mM; sodium EDTA, 0.1 mM; pH 7.4) to lyse the red blood cells.
These cells were divided into two populations and labeled with the fluorogenic
dye carboxyfluorescein diacetate succinimidyl diester (CFSE; Molecular Probes,
Eugene, OR) at a final concentration of 5 M (CFSEhigh) or 0.5 M (CFSElow).
The CFSEhigh cells were coated for 40 min at 37°C with 1 M H-2Kb-restricted
peptide VNHRFTLV. The CFSElow cells remained uncoated. Subsequently, the
CFSEhigh cells were washed and mixed with equal numbers of CFSElow cells
before 40  106 total cells were i.v. injected into each mouse. Recipient animals
were mice previously immunized with recombinant plasmids and adenoviruses.
Spleen cells of recipient mice were collected 20 h after transfer, fixed with 1.0%
paraformaldehyde, and analyzed by FACS, using a FacsCanto flow cytometer
(BD, Mountain View, CA). The percentage of specific lysis was determined using
the following formula: 1  [(%CFSEhigh immunized/%CFSElow immunized)/
(%CFSEhigh naïve/%CFSElow naïve)]  100%.
Determination of IFN- secretion by cultured spleen cells and enzyme-linked
immunospot (ELISPOT) assay for enumeration of IFN--producing cells were
performed essentially as described previously (5, 48).
For flow cytometry analyses, we used mouse splenocytes treated with ACK
buffer. Single-cell suspensions were washed in phosphate-buffered saline (PBS),
stained for 10 min at room temperature (RT) with biotinylated major histocom-
patibility complex class I (MHC I) multimer H-Kb/VNHRFTLV, and finally
stained for 20 min at 4°C with avidin-allophycocyanin (avidin-APC) and peri-
dinin chlorophyll protein (PerCP)-labeled anti-CD8 antibodies (both from BD
Pharmingen). For analyses of other cell surface markers, single-cell suspensions
from spleens of mice were stained at RT with biotinylated MHC I multimer
H-Kb/VNHRFTLV and then stained for 20 min at RT with avidin-APC and
PerCP-labeled anti-CD8 antibodies or fluorescein isothiocyanate (FITC)-labeled
anti-CD11a (clone 2D7), anti-CD11c (clone HL3), anti-CD25 (clone 7D4), anti-
CD31 (clone MEC13.3), anti-CD43 (clone S7), anti-CD44 (clone IM7), anti-
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CD49d (clone R-12), anti-CD62L (clone MEL-14), anti-CD69 (clone H1.2F3),
anti-CD95 (clone Jo2), anti-CD122 (clone TM-1), anti-CD127 (clone SB/199),
or anti-CCR5 (clone C34-3448) (all from BD Pharmingen). Anti-CD27 (clone
LG.7F9) and anti-KLRG-1 (clone MAFA) were purchased from eBioscience. At
least 100,000 cells were acquired on a BD FacsCanto flow cytometer and then
analyzed with FlowJo (Tree Star).
The surface mobilization (expression) of CD107a and the intracellular expres-
sion of cytokines (IFN- and tumor necrosis factor alpha [TNF-]) were evalu-
ated after in vitro culture of splenocytes in the presence or absence of an
antigenic stimulus. Cells were washed three times in plain RPMI and resus-
pended in cell culture medium consisting of RPMI 1640 medium, pH 7.4, sup-
plemented with 10 mM HEPES, 0.2% sodium bicarbonate, 59 mg/liter of pen-
icillin, 133 mg/liter of streptomycin, and 10% HyClone fetal bovine serum
(HyClone, Logan, UT). The viability of the cells was evaluated using 0.2% trypan
blue exclusion dye to discriminate between live and dead cells. The cell concen-
tration was adjusted to 5  106 cells/ml in cell culture medium containing
anti-CD28 (2 g/ml), brefeldin A (10 g/ml), monensin (5 g/ml), and 2 g/ml
FITC-labeled anti-CD107a (clone 1D4B; BD Pharmingen). To half of the cul-
tures, 10 M (final concentration) VNHRFTLV peptide was added. The cells
were cultivated in flat-bottom 96-well plates (Corning) in a final volume of 200
l in duplicate at 37°C in a humid environment. After a 20-h incubation, cells
were stained for surface markers with PerCP- or phycoerythrin (PE)-labeled
anti-CD8 on ice for 20 min. To detect IFN- or TNF- by intracellular staining,
cells were then washed twice in buffer containing PBS, 0.5% bovine serum
albumin (BSA), and 2 mM EDTA, fixed in a 4% PBS-paraformaldehyde solution
for 10 min, and permeabilized for 15 min in a PBS–0.1% BSA–0.1% saponin
solution. After being washed twice, cells were stained for intracellular markers by
using APC- or PE-labeled anti-IFN- (clone XMG1.2) and PE-labeled anti-
TNF- (clone MP6-XT22) for 20 min on ice. Finally, cells were washed twice and
fixed in 1% PBS-paraformaldehyde. At least 300,000 cells were acquired on a BD
FacsCanto flow cytometer and then analyzed with FlowJo.
Statistical analysis. When the variances were similar, values were expressed as
averages 	 standard deviations (SD). These values were compared by one-way
analysis of variance (ANOVA) followed by Tukey’s honestly significant differ-
ence (HSD) tests (http://faculty.vassar.edu/lowry/VassarStats.html). When the
variances varied substantially, values were expressed as medians (bars) and
sample values (dots). Values were compared by the Mann-Whitney or Kruskal-
Wallis nonparametric test. The log rank test was used to compare mouse survival
rates after challenge with T. cruzi. The differences were considered significant
when the P value was 
0.05.
RESULTS
Comparison of functional and phenotypic aspects of trans-
gene-specific CD8 T cells elicited by heterologous plasmid
DNA priming-recombinant adenovirus boosting vaccination
14 or 98 days after the last immunizing dose. In earlier studies,
we described that protective immunity against T. cruzi infection,
as measured by reductions in peak parasitemia and delayed
mouse mortality, could be achieved by heterologous plasmid
DNA priming-recombinant adenovirus boosting vaccination (13).
This protective immunity was long-lived. Mice challenged 14 or
98 days after the last immunizing dose displayed similar degrees
of protective immunity. Protective immunity mediated by these
cells correlated with the presence of effector CD8 T cells capa-
ble of mediating in vivo cytotoxic activity and of expressing, upon
short in vitro exposure to the antigen, surface CD107a and IFN-
or IFN- and TNF- (13). Based on this knowledge, we consid-
ered that it would be of interest to further characterize important
functional and phenotypic aspects of these protective CD8 T
cells elicited by heterologous plasmid DNA priming-recombinant
adenovirus boosting vaccination.
To that end, we compared several functional and phenotypic
aspects of the specific CD8 T cells present in the spleens of
vaccinated mice 14 or 98 days after the last immunizing dose.
We used C57BL/6 mice in our immunological analyses because
we were able to obtain the H-2Kb/VNHRFTLV pentamer.
This reagent is critical for proper visualization of specific
CD8 T cells. The protocol of immunization and the timing of
analyses are depicted in Fig. 1A. Initially, we estimated the
frequency of specific CD8 T cells by staining them with anti-
CD8 and the H-2Kb/VNHRFTLV pentamer (Fig. 1B to E).
Using this methodology, we did not find a significant difference
FIG. 1. Comparison of functional aspects of transgene-specific
CD8 T cells elicited by heterologous plasmid DNA priming-recom-
binant HuAd5 boosting vaccination regimen 14 or 98 days after the last
immunizing dose. (A) C57BL/6 mice were immunized as shown. Prim-
ing and boosting immunizations were performed i.m. on the indicated
days, using 100 g of plasmid DNA or 2  108 PFU of HuAd5.
Fourteen or 98 days after the HuAd5 dose, transgene-specific immune
responses were analyzed. (B to D) Splenic cells were removed, and the
frequencies of CD8 H-2Kb/VNHRFLTV cells were determined.
Results are shown as fluorescence intensities following staining with
anti-CD8–PerCP, biotinylated H-2Kb/VNHRFLTV, and avidin-APC.
The frequencies of double-positive cells inside the gates are depicted
as percentages of total splenic cells from the following groups: (i)
control mice injected with pcDNA3/Ad-gal (B), (ii) mice immunized
with pIgSPCl.9/AdASP-2 14 days earlier (C), and (iii) mice immunized
with pIgSPCl.9/AdASP-2 98 days earlier (D). Results are from one
representative of four mice. (E) The total numbers of CD8 H-2Kb/
VNHRFLTV cells in the spleens of immunized mice (n  4) were
estimated. No statistically significant difference was found between
groups of mice that were immunized with pIgSPCl.9/AdASP-2 14 and
98 days earlier. (F) Fourteen or 98 days after the last immunizing dose,
mice were injected with splenic syngeneic cells labeled with CFSE and
coated with VNHRFTLV peptide. The specific in vivo cytotoxic activ-
ity was estimated after 20 h, as described in Materials and Methods.
(G) Fourteen or 98 days after the last immunizing dose, spleen cells
were collected and the number of splenic IFN- spot-forming cells
(SFC) was estimated using an ex vivo ELISPOT assay. Results from
panels E to G are shown as averages 	 SD for 4 mice per group and
are representative of two or more independent experiments. No sta-
tistically significant difference was found between groups of mice that
were immunized with pIgSPCl.9/AdASP-2 14 and 98 days earlier.
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in the frequency or total number of splenic antigen-specific
cells between the groups of vaccinated mice.
The function of these cells was evaluated using an in vivo
cytotoxic assay and an ELISPOT assay for ex vivo determina-
tion of the number of peptide-specific IFN--secreting cells. As
shown in Fig. 1F and G, we could not detect significant differ-
ences between groups of mice that were boosted with
AdASP-2 14 and 98 days prior. These immune responses were
elicited by the recombinant vaccine, as control mice injected
with pcDNA3 followed by adenovirus beta-galactosidase
(Ad-Gal) displayed minimal antigen-specific responses.
Therefore, we concluded that the number and function of the
antigen-specific T cells were preserved during the period ana-
lyzed.
Subsequently, we evaluated the expression of surface
CD107a and intracellular cytokines following a short in vitro
restimulation with the cognate peptide VNHRFTLV. FACS
analyses of peptide-stimulated splenic CD8 T cells demon-
strated that cells from mice primed with pIgSPCl.9 and subse-
quently boosted with AdASP-2 14 and 98 days prior expressed
surface CD107a, IFN-, and TNF- (Fig. 2A and B, respec-
tively). No statistically significant difference was found in the
total frequencies of cells stained for any of these molecules
when we compared vaccinated mice boosted 14 and 98 days
prior. The frequencies of cells positive for membrane CD107a
or any of the cytokines varied from 7.49% to 17.63% for the
group boosted 14 days earlier and from 11.34% to 13.26% of
CD8 T cells for mice boosted 98 days earlier (but the differ-
ences were nonsignificant [NS]).
The expression of surface CD107a and intracellular cyto-
kines following in vitro restimulation with the cognate peptide
VNHRFTLV was dependent on immunization with pIgSPCl.9/
AdASP-2, as cells from control mice injected with pcDNA3/
Ad-gal displayed a minimal number of peptide-specific cyto-
FIG. 2. Comparison of expression of surface CD107a and intracellular cytokines by transgene-specific CD8 T cells induced by heterologous
plasmid DNA priming-recombinant HuAd5 boosting vaccination regimen 14 or 98 days after the last immunizing dose. C57BL/6 mice were
immunized according to the schedule depicted in Fig. 1A. Fourteen or 98 days after the HuAd5 immunization, splenic cells were collected and
cultured in the presence of anti-CD28 and anti-CD107a, with or without the VNHRFTLV peptide. After 12 h, cells were stained with anti-CD8
and then fixed and stained with anti-IFN- and anti-TNF-. Results are shown as fluorescence intensities for the indicated molecules on the x and
y axes. The type of cells and the in vitro stimulus are shown at the top of each graphic. Med, medium; Pep, VNHRFTLV. (A and B) FACS analyses
of CD8 cells from mice immunized with pIgSPCl.9/AdASP-2 14 (A) or 98 (B) days earlier. (C and D) Frequencies of cell populations in groups
of mice immunized with pIgSPCl.9/AdASP-2 14 or 98 days earlier. Asterisks denote statistically significant differences between groups (P 
 0.05).
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kine-expressing cells, varying from 0% to 0.16% and from
0.06% to 0.53% of CD8 T cells from mice boosted 14 and 98
days prior, respectively.
In comparing the subpopulations of cells expressing different
combinations of molecules, we found statistically significant
differences between cells from vaccinated mice boosted 14 days
prior and those from mice boosted 98 days prior. As shown in
Fig. 2C and D, the predominant CD8 T-cell subpopulation in
the spleens of mice boosted 14 days earlier comprised
CD107a IFN- TNF- cells, which accounted for 52.12%
of the cells. In mice boosted 98 days earlier with AdASP-2, this
subpopulation was reduced to 26.92% of specific CD8 T cells
(P 
 0.05). Similarly, the frequency of CD107a IFN-
CD8 T cells was reduced from 27.76% to only 3.75% during
the same time span (P 
 0.05). In contrast, the frequency of
CD107 or TNF- singly positive or CD107 TNF- dou-
ble-positive CD8 T cells increased significantly during that
period (Fig. 2C and D). In the case of CD107a cells, the
increase was rather dramatic, from 0% to 38.0% (P 
 0.05).
These results clearly demonstrate that the frequency of total
specific T cells changed little in this time span. However, the
quality of the effector T cells was not as stable and may have
changed significantly. In spite of these changes, it is important
to mention that their biologic meaning is not clear because
protective immunity was not significantly different (13).
We then compared the surface markers expressed on pro-
tective specific splenic CD8 T lymphocytes elicited by the
heterologous prime-boost regimen. For this purpose, CD8 T
cells obtained from immune mice were stained with anti-CD8,
multimer H-2Kb/VNHRFTLV, and one of several different
activation, homing, or memory markers. Fluorescence intensity
was compared to the expression of the same activation markers
on naïve CD8 T cells. As shown in Fig. 3, compared to naïve
CD8 T cells, the phenotype of double-stained CD8 H-2Kb/
VNHRFTLV cells from immune mice was CD11ahigh CD25
CD27high/low CD31low CD43high CD44high CD49d CD62Llow
CD69 CD95 CD122 KLRG-1high/low CCR5. The expres-
sion of these markers did not vary according to whether the
cells were collected 14 or 98 days after the booster injection
with AdASP-2. In fact, only two markers (CD11c and CD127)
showed discordant behavior between the two samples. Al-
though specific CD8 T cells collected from mice boosted 14
days earlier displayed upregulated expression of CD11c and
downregulated expression of CD127, their pattern of expres-
sion returned to the steady state in cells collected at day 98. In
addition to these markers, we also evaluated PD-1, CTLA-4,
and BTLA expression on specific CD8 T cells after 98 days of
boosting immunization. We found that PD-1 and CTLA-4
were expressed similarly on naïve and specific CD8 T cells,
whereas BTLA was significantly downregulated (data not
shown). Based on these analyses, we concluded that after 14
days, antigen-specific cells displayed a T effector (TE)-like
FIG. 3. Phenotypic characterization of splenic transgene-specific CD8 T cells elicited by heterologous plasmid DNA priming-recombinant
HuAd5 boosting vaccination regimen 14 or 98 days after the last immunizing dose. C57BL/6 mice were immunized according to the schedule
presented in Fig. 1A. Fourteen or 98 days after the recombinant HuAd5 dose, splenic cells were stained with anti-CD8, H-2Kb/VNHRFTLV, and
the indicated marker-specific antibody prior to analysis by FACS. The histograms show the expression of the markers on CD8 H2Kb/
VNHRFTLV T cells (blue lines) or control naive CD8 spleen cells (red lines). Analyses were performed using pools of cells from three mice
and are representative of two or more experiments performed independently. Numbers indicate the mean fluorescence intensities. In the case of
KLRG-1, percentages of positive cells are indicated.
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phenotype that subsequently changed to a TEM-like pheno-
type.
Absence of IL-12/IL-23 (p40), but not IFN-, signaling al-
ters the formation of the stable pool of antigen-specific T
effector memory cells. Because IL-12/IL-23 (p40) and IFN-
have previously been implicated in the maintenance of anti-
gen-specific memory T cells (10, 37, 52), we evaluated the fate
of these cells in genetically deficient mice 98 days after the last
immunizing dose with AdASP-2. We found that compared to
that for WT vaccinated controls, the frequency of specific
CD8 T cells labeled by the multimer H-2Kb/VNHRFTLV
was significantly lower for vaccinated mice deficient for the
expression of IL-12/IL-23 (p40) but not for IFN- (Fig. 4A).
Similarly, these KO mice also had a significant impairment
with regard to the number of cells expressing surface CD107a,
IFN-, or TNF- after in vitro stimulation with the cognate
peptide (Fig. 4B and C). In contrast, IFN--deficient mice did
not present any impairment in the generation of cells express-
ing surface CD107a or TNF- after in vitro stimulation (Fig. 4B
and C).
Heterologous prime-boost vaccination establishes a pool of
antigen-specific CD8 T cells that are relatively resistant to
immunological erosion following vaccination with recombi-
nant virus or plasmid DNA. Although memory CD8 T cells
traditionally have been considered stable over long periods,
recent evidence challenged this concept by showing that sub-
sequent infections or vaccinations may cause attrition and ero-
sion of the memory T-cell pool (14, 24, 44, 45). We tested
whether the homogeneous population of transgene-specific
TEM-like cells induced by the heterologous prime-boost vac-
cination regimen could also be the target for this attrition after
the exposure of vaccinated mice to other vaccines. We also
determined whether CD4 T-cell deficiency induced after im-
munization could impact the number or function of these cells.
To that end, immune mice were subjected to three different
treatments. A group of vaccinated mice (group 3) was immu-
nized monthly with recombinant MVA-GFP (12). A second
group (group 4) was vaccinated monthly with a plasmid DNA
vaccine containing the gag gene of HIV (34). A third group of
animals (group 5) was treated with depleting anti-CD4 MAb
every month for three consecutive months. A schematic dia-
gram of the experimental protocol can be found in Fig. 5A.
One hundred five days after the last immunizing dose with
recombinant AdASP-2, splenic cells were analyzed for the fre-
quency of pentamer-stained cells, in vivo peptide-specific cyto-
toxicity, the frequency of peptide-specific IFN--secreting
cells, and the frequency of CD8 T cells expressing surface
CD107a, IFN-, or TNF-. As depicted in Fig. 5B, despite
intragroup variability, no statistically significant difference was
observed in the frequency of H-2Kb/VNHRFTLV CD8
cells when we compared the vaccinated mice of groups 2, 3, 4,
and 5. Also, the peptide-specific in vivo cytotoxicities of these
mice were remarkably high and similar (Fig. 5C).
As shown in Fig. 5D, in the case of the frequency of peptide-
specific IFN--secreting cells measured by ELISPOT assay, we
also failed to detect statistically significant reductions in the
numbers of cells from vaccinated mice subjected to the differ-
ent treatments. The enumerations of the total frequency of
CD8 T cells expressing surface CD107a, IFN-, or TNF- did
not differ significantly among groups 2, 3, 4, and 5 (Fig. 5E).
Also, when we estimated the numbers of cells expressing dif-
ferent combinations of these molecules, we found no signifi-
cant differences among cells collected from vaccinated mice of
groups 2, 3, 4, and 5. As shown in Fig. 5F, the predominant
CD8 T-cell subpopulations in the spleens of all mice were
CD107a singly positive cells and/or CD107a IFN- TNF-
triple-positive cells. Other subpopulations also maintained
similar frequencies. These results demonstrated that the fre-
quency of each subpopulation of specific T cells was relatively
stable despite immunological treatments.
FIG. 4. Importance of IFN- or IL-12/IL-23 signaling pathways in
the maintenance of transgene-specific CD8 memory T cells elicited
by a heterologous plasmid DNA priming-recombinant HuAd5 boost-
ing vaccination regimen. C5BL/6 WT, IFN- KO, and IL-12/IL-23
(p40) KO mice were immunized according to the schedule presented
in Fig. 1A. Ninety-eight days after the final immunizing dose, splenic
cells were analyzed for the frequencies of CD8 H-2Kb/VNHRFLTV
cells (A) or cells expressing surface CD107a, IFN-, or TNF- upon in
vitro restimulation (B and C). In panels A and B, results are shown as
medians (bars), and each dot represents a mouse. Asterisks denote
significantly lower frequencies of specific CD8 T cells in the IL-12/
IL-23 (p40) KO mice immunized with pIgSPCl.9/AdASP-2 than in the
immunized WT mice (P 
 0.05). The cross in panel C denotes a
significantly higher frequency of specific CD8 T cells in the group of
IFN- KO mice immunized with pIgSPCl.9/AdASP-2 than in the im-
munized WT mice (P 
 0.05). The results in panel C are shown as
medians for 4 or 5 mice per group and are representative of two
independent experiments. Individual mouse results were omitted for
clarity but were used for the statistical calculations.
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Analyses of CD44 and CD62L on the surfaces of the H-2Kb/
VNHRFTLV CD8 cells of each mouse group revealed that
their levels were similar, with all cells being CD44high
CD62Llow (data not shown).
Finally, to test whether these cells were still indeed func-
tional, we evaluated protective immunity against a challenge
with a lethal dose of T. cruzi. For this purpose, we vaccinated
highly susceptible A/Sn mice and subsequently injected these
animals with MVA-GFP, as depicted in Fig. 6A. We selected
the MVA immunization protocol because it was conceivable
that a stronger immune response would be generated by this
viral vaccine than by the plasmid. Also, the depletion of CD4
FIG. 5. Immune responses of transgene-specific CD8 T cells elic-
ited by a heterologous plasmid DNA priming-recombinant HuAd5
boosting regimen in mice subjected to immune erosion protocols.
(A) Schematic representation of the protocol used for immune erosion
in mice immunized with a heterologous prime-boost regimen. Mice
were immunized according to the schedule presented in Fig. 1A. On
the indicated days, mice were injected with recombinant MVA-GFP
(107 PFU i.v.) or plasmid DNA (50 g i.m. per mouse per dose) or
treated daily with doses of 0.5 mg of anti-CD4 MAb for three consec-
utive days. (B) Splenic cells were collected, and the frequencies of
CD8 H-2Kb/VNHRFLTV cells were determined. Results are ex-
pressed as medians (bars), and each dot represents a mouse. (C) Mice
were injected with splenic syngeneic cells labeled with CFSE and
coated with VNHRFTLV peptide. The specific in vivo cytotoxic activ-
ity was estimated after 20 h, as described in Materials and Methods.
Results are expressed as means plus SD (n  4). (D) Spleen cells were
collected, and we estimated the number of splenic IFN- spot-forming
cells (SFC) by using an ex vivo ELISPOT assay. Results are expressed
as means plus SD (n  4). (E and F) Splenic cells were collected and
cultured in the presence of anti-CD28 and FITC-labeled anti-CD107a,
with or without the VNHRFTLV peptide. After 12 h, cells were
stained with PerCP-labeled anti-CD8, fixed, and stained with APC-
labeled anti-IFN- and PE-labeled anti-TNF-. Results are expressed
as medians (bars), and each dot represents a mouse (n  4). In panel
F, individual mouse results were omitted for clarity but were used for
the statistical calculations. Results are representative of two indepen-
dent experiments.
FIG. 6. Protective immune response in mice vaccinated with the
heterologous plasmid DNA priming-recombinant adenovirus boosting
regimen and subjected to an immune erosion protocol. (A) A/Sn mice
were immunized and subsequently treated with recombinant MVA-
GFP (107 PFU i.v.) on the indicated days. These mice were then
challenged s.c. with 150 T. cruzi blood trypomastigotes. (B) The num-
ber of parasites in the blood was followed from day 8 to day 13. The
parasitemia for each mouse group is presented as the mean	 SD (n
10). Asterisks denote groups vaccinated with pIgSPCl.9/AdASP-2 that
had significantly lower parasitemia (P 
 0.05) than control animals
injected with pcDNA3/Ad-gal. No statistically significant difference
was observed between each group and mice that had also been treated
with recombinant MVA. (C) Kaplan-Meier curves for survival of
mouse groups immunized and challenged as described above (n  10).
Mice from groups vaccinated with pIgSPCl.9/AdASP-2 survived sig-
nificantly longer than control animals injected with pcDNA3/Ad-gal
(P 
 0.05). No statistically significant difference was observed between
mice that were treated or not with recombinant MVA. Results were
pooled from two experiments.
2126 RIGATO ET AL. INFECT. IMMUN.
T cells would not provide any information, as we already know
that these cells are important for protective immunity after
challenge with T. cruzi (13).
After an infectious challenge, we followed the parasitemia
and survival of the mice that had been vaccinated with pIgSP-
Cl.9/AdASP-2 and injected or not with MVA-GFP. In these
highly susceptible mice, high parasitemia correlates with in-
tense tissue infection (B. C. de Alencar, J. R. de Vasconcelos,
and M. M. Rodrigues, unpublished data). As shown in Fig. 6B,
the parasitemia of both groups of mice immunized with ASP-2
was significantly lower than that in control mice injected with
pcDNA3 followed by Ad-Gal (P 
 0.05). However, no dif-
ference was observed between mice vaccinated with pIgSP-
Cl.9/AdASP-2 and injected with MVA-GFP and their coun-
terparts that were not injected (P  NS). Similarly, no
difference between these two groups of mice was found in
terms of survival rates (P  NS). Both groups survived longer
than those injected with pcDNA3 followed by Ad-Gal (P 

0.05 in both cases). Histological analyses of the heart tissues of
these mice failed to identify an inflammatory reaction or in-
fected cells, as we described previously (13, 49).
DISCUSSION
A key question in the development of new or improved
vaccines is how to generate protective long-lived memory T
cells by use of nonliving formulations. We previously described
that a heterologous prime-boost vaccination regimen using
recombinant plasmid DNA followed by a recombinant HuAd5
vector was an effective strategy for the induction of long-lived
CD8 T-cell-dependent protective immunity against systemic
infection with a parasitic protozoan (13). In spite of a number
of studies characterizing the phenotype and function of immu-
noprotective memory T cells following infections with viruses
and bacteria, the characteristics of memory T cells present in
mice subjected to a heterologous prime-boost vaccination reg-
imen using recombinant plasmid DNA followed by recombi-
nant HuAd5 remain to be elucidated.
The lack of information on this subject led us to perform a
detailed comparison of the short- and long-term populations of
available CD8 T cells following heterologous prime-boost
immunization. We found that in spite of the timing, both pop-
ulations overlapped greatly with regard to functional and phe-
notypic characteristics. We observed that the frequency and
total number of splenic specific CD8 T cells were maintained
during this time span. Not only was the number of splenic cells
preserved, but these cells also exhibited strong cytotoxic activ-
ity and secreted IFN- when target cells coated with the cog-
nate peptide were encountered in vivo and ex vivo (ELISPOT
assay), respectively. The functional properties retained after
extended periods are likely linked to the protective capacity of
these cells because, as we observed previously, both perforin
and IFN- are important for the effector mechanisms medi-
ated by CD8 T cells against T. cruzi infection (13). It is
important to mention that we studied only H-2Kb-restricted
CD8 T cells specific for the immunodominant epitope
VNHRFTLV. Attempts to find other subdominant epitopes in
ASP-2 recognized by H-2b-restricted CD8 T cells have failed
so far (M. R. Dominguez and M. M. Rodrigues, unpublished
data). Nevertheless, in other mouse strains where there might
be dominant and subdominant CD8 epitopes, similar analyses
of the phenotype may provide differences between populations
of distinct specificities.
Although the number and frequency of specific splenic T
cells did not change during the time span studied, the expres-
sion of surface CD107a, IFN-, or TNF- upon in vitro stim-
ulation with the cognate peptide did. Two weeks after the last
immunizing dose, the frequency of triple-positive multifunc-
tional cells was 50% of specific CD8 T cells. This frequency
was reduced to approximately half that in the spleens of mice
immunized 14 weeks earlier. The reason for this change is not
clear. Whether these cells failed to survive or differentiated to
another phenotype will be interesting to study further. A sim-
ilar phenomenon was also observed among the population of
CD8 T cells simultaneously expressing surface CD107a and
TNF-. In contrast, the frequency of singly positive cells ex-
pressing surface CD107a increased during the same period.
Whether this increase was due to accelerated proliferation or
due to differentiation to another T-cell subpopulation remains
unknown. In spite of these changes, we do not consider that
they had a significant biological meaning, as mice vaccinated 14
or 98 days previously were equally well protected against an
infectious challenge (13) (Fig. 6).
Not only did specific CD8 T cells retain their functional
characteristics, but the surface phenotypes of the specific
CD8 T cells were also quite similar 14 and 98 days after the
last immunizing dose with AdASP-2. The phenotype of the
first group was similar to that previously described for short-
lived effector cells (CD44high CD11ahigh CD62Llow CD127
KLRG-1high) (reviewed in references 4, 25, 36, and 41). The
latter subpopulation resembled TEM cells (CD44high
CD11ahigh CD62Llow CD127 KLRG-1low) (reviewed in ref-
erences 4, 25, 36, and 41). However, in our case, after staining
for the KLRG-1 marker, we found that cells in both groups
expressed various levels of this molecule. A similar population
of specific CD8 T cells has been described following heter-
ologous prime-boost immunizations with vesicular stomatitis
virus (or plasmid DNA) followed by recombinant vaccinia vi-
rus (35). In contrast, we did not observe the emergence of
typical TCM cells (CD44high CD11ahigh CD62Lhigh CD127
KLRG-1low), even after an extended period of 6 months (data
not shown). This observation also corroborates with previously
published observations from Masopust et al. (35). Together,
these data suggest that the heterologous prime-boost regimen
may change the CD8 T-cell differentiation program, signifi-
cantly delaying or perhaps even blocking the development of
TCM-like cells. We also evaluated the surface phenotype of
these specific CD8 T cells after a challenge. Essentially, we
found that these cells maintained the TEM-like phenotype for
up to 6 months after the challenge with T. cruzi (data not
shown).
The idea that fully active TEM-like cells can survive for
relatively long periods may have an important impact on the
design of vaccines against pathogens that require TEM cells
for resistance to reinfection. In fact, our results support the
idea that TEM cells may contribute greatly to the protective
immune response, as these cells can still provide immunity
against T. cruzi-mediated systemic infection (13) (Fig. 6B and
C). Previous observations that TEM cells can mediate protec-
tive immunity were provided in the cases of reinfections with
VOL. 79, 2011 PHENOTYPIC CHARACTERISTICS OF PROTECTIVE CD8 T CELLS 2127
vaccinia and Sendai viruses (3, 40). However, the TCM cell
subset was shown to be the most relevant for protective im-
munity against certain viruses, protozoan parasites, and tumors
(27, 51, 56). This also seems to be the case during infection
with T. cruzi. Following successful drug therapy of infected
mice, there is the emergence of a TCM-like subpopulation
(CD62Lhigh) that is highly effective in protecting against rein-
fection (6). Similar experiments could not be performed with
our mouse model because treatment of mice with drugs did not
prevent parasite infection (M. M. Rodrigues, unpublished ob-
servation). The parasite strain that we used seems to be resis-
tant to conventional drug therapy.
The reason that these cells retained the TEM-like pheno-
type and the mechanism by which they did so may reflect
persistent expression of the transgene. Earlier studies of mice
vaccinated with a simian replication-defective adenovirus dem-
onstrated unequivocally that the transgene product was still
available for antigen presentation as long as 16 weeks after a
single immunizing dose (46). Antigen persistence was con-
firmed by experiments demonstrating a causal relationship be-
tween the duration of transgene expression following immuni-
zation with a HuAd5 vaccine and maintenance of the specific
CD8 T cells (16). The same group previously reported that
maintenance of the CD8 T-cell memory population following
HuAd5 immunization does not require active thymopoiesis,
arguing against continual recruitment of naïve T cells (55). The
authors of that study proposed that the early memory popula-
tion produced by HuAd5 is sustained by continual restimula-
tion; this is consistent with the high levels of KLRG-1 among
the members of the memory population, because KLRG-1 is
considered to be an indicator of recent and repetitive antigenic
stimulation (47). The precise site where antigen is produced
continually or whether pulsed APC retains the ability to stim-
ulate T cells over the long term is unknown at present.
One of the limitations of our analyses was the fact that we
presented results solely for splenic T cells. Compatible with the
absence of CD62L on these cells, we could not find significant
amounts of specific CD8 T cells in the draining lymph nodes
98 days after the last immunizing dose (data not shown). The
absence of specific CD8 T cells in the lymph nodes was also
noted by Masopust et al. following heterologous prime-boost
immunizations (35). Nevertheless, following heterologous
prime-boost immunizations, specific CD8 T cells were found
residing in the gut, lungs, peripheral blood, and liver (35). It is
possible that these cells may also reach the skin (54). Also, up
to now, we have limited information with regard to where the
CD8 T cells encounter and eliminate parasite-infected cells,
a subject that is critical for understanding the immune re-
sponse.
Because our model provided an interesting system to eval-
uate the requirements for the maintenance of long-lived pro-
tective CD8 TEM-like cells, in the second part of our study
we addressed the question of whether IL-12/IL-23 (p40) or
IFN- activation pathways are important, using genetically de-
ficient mice. We found that expression of IL-12/IL-23 (p40),
but not IFN-, was critical for the long-term survival of these
mice. It is important that the absence of IL-12/IL-23 (p40)
resulted in smaller amounts of specific CD8 T cells, as mea-
sured by staining with the H-2kb/VNHRFTLV pentamer 14
days after the booster vaccination. Nevertheless, at that time,
the frequencies of IFN--producing cells were not statistically
different between WT and IL-12/IL-23 (p40) KO mice (data
not shown). Therefore, it seems that IL-12/IL-23 (p40) reduces
the total number of specific cells at early time points, but it also
diminishes the number of transgene-specific cytokine-produc-
ing cells after extended periods (Fig. 4). Consistent with the
small number of specific CD8 T cells, immunized IL-12/IL-23
(p40) KO mice succumbed to infection after challenge (data
not shown). This result should be interpreted with caution,
however, because it would be impossible to attribute the high
susceptibility of the IL-12/IL-23 (p40) KO mice only to a defect
of specific CD8 T cells. The absence of this cytokine impairs
a number of other immunological functions, including the ex-
pansion of Th1 CD4 T cells and NKT and NK cells, all of
which actively participate during the immune response to T.
cruzi infection (7, 15, 23, 30, 42).
A critical role of the IL-12 signaling pathway in the induc-
tion and maintenance of memory CD8 T cells was recently
studied in several experimental models, and differences were
noticed (2, 37, 52). These differences probably reflect a distinct
interface of host-pathogen interactions, such as the tissue dis-
tribution, multiplication rate, etc.
The idea that memory CD8 T cells are stable was chal-
lenged recently by a number of publications showing that sub-
sequent infections or vaccinations may cause attrition and ero-
sion of the memory T-cell pool (14, 24, 44, 45). The fact that we
had a homogeneous population of specific CD8 TEM-like
cells allowed us to test their stability. To this end, we immu-
nized the mice with unrelated recombinant MVA or plasmid
DNA. We observed that both treatments had a limited impact
on the number or quality of these memory TEM-like cells, as
measured by different functional immunological assays. Most
importantly, the presence of protective CD8 cells was not
altered in mice vaccinated with recombinant MVA. Our results
are in agreement with more recent data showing that T-cell
receptor (TCR)-transgenic activated CD8 T cells are not
eliminated by subsequent infections with recombinant viruses
or bacteria (50). Therefore, we concluded that the intense
immune response obtained by subsequent immunization with
viruses or plasmid DNA will probably not compromise the
efficiency of the heterologous prime-boost immunization reg-
imen. Whether immunizations with other strong vaccines will
interfere with TEM-like cell stability remains to be deter-
mined. This question is also valid for other viral, bacterial,
protozoan, and helminthic infections.
In previous studies, it was reported that the main subset of
CD8 T cells targeted for erosion are TEM cells (14, 24). Our
results argue against this finding, as we observed that not all
CD8 TEM cells are targeted for MVA-induced erosion as
described previously (24). It is plausible to speculate that the
“quality” of the TEM cells elicited by the heterologous prime-
boost regimen involving plasmid DNA and recombinant
HuAd5 may differ from that, for example, of TEM cells gen-
erated by Listeria monocytogenes infection (24). Notably, a
certain degree of heterogeneity has already been noted in the
TEM CD8 cell subpopulation: these cells can be subdivided
further into CD43 CXCR3, CD43 CXCR3, and CD43
CXCR3 groups (21).
We also evaluated the requirement of CD4 T cells for the
maintenance of TEM-like CD8 T cells. We previously ob-
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served that the expansion of these cells was dependent on the
presence of CD4 T cells during priming. In CD4-deficient
mice, we observed a reduction of 10-fold in the number of
IFN--secreting CD8 T cells measured by ELISPOT assay
(13). In spite of the dependence of CD4 T cells on priming,
their depletion following vaccination did not significantly mod-
ify their number or function (Fig. 5). On one side, we observed
that specific CD8 T-cell expansion in our model system was
dependent on CD4 T cells. On the other hand, the depletion
of CD4 T cells after boosting did not significantly reduce the
number of CD8 T cells. Together, these observations suggest
that the specific CD8 T cells we observed after 98 days were
not primed recently. Most likely, these cells were maintained
by either homeostatic proliferation, antigenic restimulation, or
both.
In summary, our study describes some important character-
istics of the memory CD8 T-cell population elicited by het-
erologous prime-boost vaccination that might be key for the
generation of long-lived protective immunity against intracel-
lular parasitic protozoans. This model also establishes a pop-
ulation of protective TEM-like cells that may be interesting for
studies of T-cell transcriptional adaptations for long-term sur-
vival and function, which may be distinct from those of TCM
CD8 cells.
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